Journal article
Tigecycline Is Modified by the Flavin-Dependent Monooxygenase TetX †
Abstract
The clinical use of tetracycline antibiotics has decreased due to the emergence of efflux and ribosomal protection-based resistance mechanisms. Currently in phase III clinical trials, the glycylcycline derivative tigecycline (GAR-936) containing a 9-tert-butylglycylamido group is part of a new generation of tetracycline antibiotics developed during the 1990s. Tigecycline displays a broad spectrum of antibacterial activity and circumvents the …
Authors
Moore IF; Hughes DW; Wright GD
Journal
Biochemistry, Vol. 44, No. 35, pp. 11829–11835
Publisher
American Chemical Society (ACS)
Publication Date
September 1, 2005
DOI
10.1021/bi0506066
ISSN
0006-2960